408.76
-1.89 (-0.46%)
| Previous Close | 410.65 |
| Open | 406.50 |
| Volume | 1,301,810 |
| Avg. Volume (3M) | 1,411,517 |
| Market Cap | 105,267,552,256 |
| Price / Earnings (Forward) | 21.64 |
| Price / Sales | 9.67 |
| Price / Book | 6.55 |
| 52 Weeks Range | |
| Earnings Date | 3 Feb 2025 - 7 Feb 2025 |
| Profit Margin | -4.51% |
| Operating Margin (TTM) | 40.82% |
| Diluted EPS (TTM) | -1.90 |
| Quarterly Revenue Growth (YOY) | 11.60% |
| Quarterly Earnings Growth (YOY) | 1.00% |
| Total Debt/Equity (MRQ) | 11.35% |
| Current Ratio (MRQ) | 2.47 |
| Operating Cash Flow (TTM) | -842.60 M |
| Levered Free Cash Flow (TTM) | 3.06 B |
| Return on Assets (TTM) | 12.05% |
| Return on Equity (TTM) | -2.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vertex Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 0.08% |
| % Held by Institutions | 96.15% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 586.00 (UBS, 43.36%) | Buy |
| Median | 497.00 (21.59%) | |
| Low | 408.00 (Canaccord Genuity, -0.19%) | Sell |
| Average | 496.56 (21.48%) | |
| Total | 10 Buy, 5 Hold, 1 Sell | |
| Avg. Price @ Call | 449.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 23 Dec 2024 | 500.00 (22.32%) | Buy | 405.27 |
| 05 Nov 2024 | 503.00 (23.06%) | Buy | 499.88 | |
| Scotiabank | 23 Dec 2024 | 430.00 (5.20%) | Hold | 405.27 |
| 05 Nov 2024 | 486.00 (18.90%) | Hold | 499.88 | |
| Truist Securities | 23 Dec 2024 | 460.00 (12.54%) | Buy | 405.27 |
| BMO Capital | 20 Dec 2024 | 520.00 (27.21%) | Buy | 397.27 |
| Barclays | 20 Dec 2024 | 418.00 (2.26%) | Hold | 397.27 |
| HC Wainwright & Co. | 20 Dec 2024 | 535.00 (30.88%) | Buy | 397.27 |
| 21 Oct 2024 | 600.00 (46.79%) | Buy | 478.09 | |
| B of A Securities | 19 Dec 2024 | 522.00 (27.70%) | Buy | 396.64 |
| 14 Oct 2024 | 541.00 (32.35%) | Buy | 484.82 | |
| Stifel | 16 Dec 2024 | 494.00 (20.85%) | Hold | 468.09 |
| Jefferies | 09 Dec 2024 | 550.00 (34.55%) | Buy | 473.98 |
| Citigroup | 14 Nov 2024 | 575.00 (40.67%) | Buy | 483.96 |
| Canaccord Genuity | 06 Nov 2024 | 408.00 (-0.19%) | Sell | 493.64 |
| Cantor Fitzgerald | 05 Nov 2024 | 480.00 (17.43%) | Buy | 499.88 |
| 08 Oct 2024 | 480.00 (17.43%) | Buy | 458.94 | |
| Morgan Stanley | 05 Nov 2024 | 476.00 (16.45%) | Hold | 499.88 |
| 01 Oct 2024 | 474.00 (15.96%) | Hold | 469.76 | |
| RBC Capital | 05 Nov 2024 | 451.00 (10.33%) | Hold | 499.88 |
| 09 Oct 2024 | 437.00 (6.91%) | Hold | 467.97 | |
| UBS | 05 Nov 2024 | 586.00 (43.36%) | Buy | 499.88 |
| 17 Oct 2024 | 562.00 (37.49%) | Buy | 498.73 | |
| Oppenheimer | 30 Oct 2024 | 540.00 (32.11%) | Buy | 475.08 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |